Lyme disease vaccine - GlaxoSmithKline/Valneva

Drug Profile

Lyme disease vaccine - GlaxoSmithKline/Valneva

Alternative Names: Borrelia vaccine - GlaxoSmithKline/Valneva; Lyme borreliosis vaccine - GlaxoSmithKline/Valneva; VLA 15

Latest Information Update: 12 Dec 2016

Price : $50

At a glance

  • Originator Intercell
  • Developer Valneva
  • Class Bacterial vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Lyme disease

Most Recent Events

  • 23 Feb 2017 Valneva plans a phase II trial for Lyme disease
  • 09 Dec 2016 Phase-I clinical trials in Lyme disease (Prevention) in Belgium, USA (IM)
  • 09 Dec 2016 The US FDA and European regulatory authorities approve IND application and Clinical Trial Application, respectively, for a phase I trial for Lyme disease (Prevention)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top